Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akoya Biosciences, Inc.

1.10
+0.01501.38%
Post-market: 1.100.00000.00%16:05 EDT
Volume:174.19K
Turnover:189.39K
Market Cap:54.80M
PE:-0.98
High:1.13
Open:1.05
Low:1.02
Close:1.09
Loading ...

BRIEF-Kent Lake Files Definitive Proxy Statement And Sends Letter To Quanterix Shareholders

Reuters
·
17 Apr

Kent Lake: Urges Quanterix Shareholders to Vote Against Akoya Merger Proposals

THOMSON REUTERS
·
17 Apr

Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

Business Wire
·
17 Apr

Akoya Biosciences Is Maintained at Neutral by Piper Sandler

Dow Jones
·
14 Apr

Kent Lake Comments on Quanterix’s Value Destructive Bridge Financing for Financially Troubled Akoya

Business Wire
·
07 Apr

BRIEF-Akoya Biosciences - On April 2, Entered Securities Purchase Agreement With Quanterix Corporation

Reuters
·
04 Apr

Akoya Biosciences - on April 2, Entered Securities Purchase Agreement With Quanterix Corporation

THOMSON REUTERS
·
04 Apr

Akoya Biosciences Inc -Pursuant to Securities Purchase Agreement, Co to Issue Convertible Notes up to $30 Million - SEC Filing

THOMSON REUTERS
·
04 Apr

Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion

TIPRANKS
·
02 Apr

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

GlobeNewswire
·
02 Apr

Akoya Biosciences Shares Fall After Downgrade From Stephens

MT Newswires Live
·
26 Mar

Akoya Biosciences Cut to Equal-Weight From Overweight by Stephens & Co.

Dow Jones
·
25 Mar

Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80

MT Newswires Live
·
25 Mar

Cautious Outlook on Akoya Biosciences Amid Acquisition Uncertainties and Mixed Financial Performance

TIPRANKS
·
25 Mar

BRIEF-Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences

Reuters
·
24 Mar

Tikvah Management- Announces Intention to Vote Against Quanterix's Proposed Merger With Akoya Biosciences

THOMSON REUTERS
·
24 Mar

Hold Rating on Akoya Biosciences Amid Acquisition Uncertainties and Financial Challenges

TIPRANKS
·
24 Mar

North American Morning Briefing: Stock Futures Rise on Tariff Optimism

Dow Jones
·
24 Mar

Akoya Biosciences Price Target Maintained With a $3.50/Share by Stephens & Co.

Dow Jones
·
18 Mar

Q4 2024 Quanterix Corp Earnings Call

Thomson Reuters StreetEvents
·
18 Mar